Virtus Biotech Clinical Trials ETF
11 hedge funds and large institutions have $8.37M invested in Virtus Biotech Clinical Trials ETF in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
3.51% more ownership
Funds ownership: 35.52% → 39.02% (+3.5%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
14% less capital invested
Capital invested by funds: $9.72M → $8.37M (-$1.35M)
21% less funds holding
Funds holding: 14 → 11 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$862K |
| 2 |
Jane Street
New York
|
+$201K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$159K |
| 4 |
Morgan Stanley
New York
|
+$40.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$470K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$317K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$48.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$28.7K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$19.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3.54M | +$862K | +31,709 | +27% |
|
2
Goldman Sachs
New York
| $2.38M | – | – | – |
|
|
3
LPL Financial
San Diego,
California
| $651K | -$470K | -17,269 | -39% |
|
|
4
Jane Street
New York
| $642K | +$201K | +7,409 | +38% |
|
|
AWCI
5
Alpine Woods Capital Investors
Purchase,
New York
| $584K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $332K | +$159K | +5,834 | +72% |
|
|
7
Morgan Stanley
New York
| $214K | +$40.2K | +1,480 | +20% |
|
|
LTFS
8
Ladenburg Thalmann Financial Services
Miami,
Florida
| $12K | -$48.9K | -1,800 | -78% |
|
|
9
UBS Group
Zurich,
Switzerland
| $6K | -$28.7K | -1,055 | -82% |
|
|
10
Wells Fargo
San Francisco,
California
| $5K | -$19.8K | -729 | -76% |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $2.62K | – | – | – |
|
|
12
Stifel Financial
St. Louis,
Missouri
| – | -$317K | -11,051 | Closed |
|
13
Bank of America
Charlotte,
North Carolina
| – | -$17K | -590 | Closed |
|
14
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$4K | -150 | Closed |
|
BBC Hedge Fund Activity: Q3 2019 in Review
11 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2019, worth a combined $8.37M — down 14% from $9.72M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BBC and 0 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Royal Bank of Canada, adding an estimated $862K. The largest seller was LPL Financial, cutting an estimated $470K.
- 11 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2019, down from 14 in Q2 2019.
- Funds reported $8.37M of Virtus Biotech Clinical Trials ETF stock for Q3 2019, down 14% quarter-over-quarter.
- 0 funds opened new Virtus Biotech Clinical Trials ETF positions in Q3 2019 and 3 closed out, a net change of -3 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2019 was Royal Bank of Canada, an estimated $862K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2019 was LPL Financial, an estimated $470K sold.
Based on aggregated 13F filings for Q3 2019.